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Abstract
Introduction: To effectively address HIV/AIDS in Africa, evidence on preventing new infections and providing effective
treatment is needed. Ideally, decisions on which interventions are effective should be based on evidence from randomized
controlled trials (RCTs). Our previous research described African RCTs of HIV/AIDS reported between 1987 and 2003. This
study updates that analysis with RCTs published between 2004 and 2008.
Objectives: To describe RCTs of HIV/AIDS conducted in Africa and reported between 2004 and 2008.
Methods: We searched the Cochrane HIV/AIDS Specialized Register in September 2009. Two researchers independently
evaluated studies for inclusion and extracted data using standardized forms. Details included location of trials, interventions,
methodological quality, location of principal investigators and funders.
Results: Our search identified 834 RCTs, with 68 conducted in Africa. Forty-three assessed prevention-interventions and 25
treatment-interventions. Fifteen of the 43 prevention RCTs focused on preventing mother-to-child HIV transmission.
Thirteen of the 25 treatment trials focused on opportunistic infections. Trials were conducted in 16 countries with most in
South Africa (20), Zambia (12) and Zimbabwe (9). The median sample size was 628 (range 33-9645). Methods used for the
generation of the allocation sequence and allocation concealment were adequate in 38 and 32 trials, respectively, and 58
reports included a CONSORT recommended flow diagram. Twenty-nine principal investigators resided in the United States
of America (USA) and 18 were from African countries. Trials were co-funded by different agencies with most of the funding
obtained from USA governmental and non-governmental agencies. Nineteen pharmaceutical companies provided partial
funding to 15 RCTs and African agencies co-funded 17 RCTs. Ethical approval was reported in 65 trials and informed consent
in 61 trials.
Conclusion: Prevention trials dominate the trial landscape in Africa. Of note, few principal investigators and funders are
from Africa. These findings mirror our previous work and continue to indicate a need for strengthening trial research
capacity in Africa.
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Introduction
Combating HIV/AIDS relies on the preventionof new infections
and on providing effective antiretroviral therapy to patients with
disease. In 2008, there were an estimated 33.4 million people living
with HIV, 2.7 million new infections and 2 million HIV/AIDS
related deaths. Only 33% of HIV-infected women received
antiretroviral drugs to reduce the risk of mother-to-child transmis-
sion of HIV. Africa is the region most affected by HIV/AIDS [1]. It
is thus critical that research is carefully conducted and responds to
the health priorities of the continent. This is particularly important
in Africa as the economic resources of the continent are limited [2].
The randomized controlled trial (RCT) is the gold standard for
evaluating effects of healthcare interventions [3]. Researchers,
health workers, policy-makers and consumers need information on
planned, ongoing and completed clinical trials to enable them to
effectively assess interventions for preventing or treating HIV/
AIDS and related conditions and to plan future research. Our
previous work [4] provided a descriptive analysis of RCTs of
HIV/AIDS interventions conducted in Africa and reported up to
the end of 2003. The current study updates that analysis with
RCTs published from the beginning of 2004 up to the end of
2008. This new data will inform African stakeholders of gaps in
research and highlight current achievements.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28759Objectives
To identify, describe and analyze RCTs of HIV/AIDS interven-
tions conducted in Africa and reported between 2004 and 2008.
Methods
Maintenance of the Cochrane HIV/AIDS Specialized
Register
The Register comprises trial records stored in an MS Access
database and is maintained by a dedicated information specialist
and an assistant. We conduct quarterly searches of two major
electronic databases, PUBMED and EMBASE, using the
Cochrane highly sensitive search strategy (Appendix S1) for
retrieving RCTs [5] coupled with a comprehensive HIV/AIDS
search string (Appendix S2) [4]. We search the Cochrane Central
Register of Controlled Trials (CENTRAL) once a year. Four
independent hand-searchers with epidemiological training identify
any HIV/AIDS RCTs and controlled clinical trials in the search
results for inclusion in the Register. A senior epidemiologist
conducts quality control on a random 10% sample of these
records. In September 2009, we used the built-in search tool of the
Register to identify records coded as RCT and published between
2004 and 2008.
Searching for trials, data extraction and analysis
We searched the Cochrane HIV/AIDS Specialized Register of
trials (the Register). The abstracts retrieved were exported from
the Register into ProCite and printed. Each abstract was reviewed
by two independent researchers to identify RCTs conducted in
Africa between 2004 and 2008. Full-text articles were obtained for
potentially eligible RCTs and those for which we were uncertain.
Two researchers independently read the articles and determined
final inclusion according to the criteria in Table 1. Eligibility for
studies that were unclear was verified by the third researcher. Data
were independently extracted and compared by two researchers
using a standardized data-extraction form and discrepancies were
resolved with the third researcher. The third researcher also
conducted quality control on a 10% sample selected through a
random number generator in MS Excel.
Extracted data included details of principal investigators, trial
location, details of interventions and methodological quality of
RCTs (Table 2). Data were single-captured in MS Access and
descriptively analyzed.
Results
Our search for ‘‘RCTs’’ in the Register identified 834 records.
Of these, 154 references described potentially relevant African
RCTs. The remaining 680 references referred to RCTs conducted
in non-African countries. With the inclusion of two additional
cross references, the number of potential African RCTs increased
to 156. We were unable to trace the reference for one study [6],
and could not obtain full reports for two [7,8], thus these three
studies were excluded. After assessing eligibility, 97 references
were included. Figure 1 shows the flow diagram including the
reasons for exclusion of 59 references.
Of the 97 references included, 68 were primary RCTs reported
for the first time during 2004–2008. Eight of the 68 primary RCTs
had nine more references published during the same period.
Twelve references reported on four RCTs already published
before 2004 and included in the previous analysis [4]. We
identified eight references to published protocols, three of which
had primary RCTs published in the period under study. We
extracted data on the 68 primary RCTs. Where an RCT was
reported in more than one reference, we used data contained in all
the related references.
Sources of Trials
All trials included in the analysis were published as journal
articles. Nine were published in The Lancet,s e v e ni nAIDS and six
in the New England Journal of Medicine. Other journals included the
American Journal of Clinical Nutrition and Journal of Infectious Diseases
with four articles each; the American Journal of Obstetrics and
Gynecology, BMJ, PLoS ONE and the Journal of Acquired Immune
Deficiency Syndromes had three articles each. The remaining 26
trials were published in 20 different journals. The 2008 impact
factor for the journals with one published article ranged between
1.517 and 7.069 (seven journals). Five journals with two
published articles each had an impact factor range between
2.304 and 31.718. The remaining eight journals were not listed in
the Institute for Scientific Information Web of Knowledge
Journal Citation Report for 2008. All study reports were
published in English language journals. Sources of trials are
s h o w ni nA p p e n d i xS 3 .
Location and centre types of African RCTs
Seven RCTs were conducted at multiple sites across 11
countries which included Benin, Cameroon, Ethiopia, Ghana,
Malawi, Nigeria, South Africa Tanzania, Uganda Zimbabwe and
Zambia. Thirty-six RCTs were conducted in multiple centres in a
single country. Of these, South Africa hosted 12 trials, Tanzania
and Zambia hosted five trials each, and Malawi hosted four trials,
Kenya, Nigeria and Zimbabwe hosted two trials each. Botswana,
Burkina-Faso, Rwanda and Uganda each hosted one multi-site
trial each.
Table 1. Eligibility criteria for Randomized Controlled Trials included.
Inclusion criteria Exclusion criteria
Intervention Efficacy or effectiveness of HIV/AIDS specific interventions including pilot studies Safety and acceptability trials
Efficacy or effectiveness of non-HIV/AIDS specific interventions, but in or with a
subgroup (at least 10%) of HIV infected participants
Trials measuring behavioral interventions without HIV incidence
Location Conducted wholly or partly in Africa Trials conducted in Africans living outside the continent
Participants Infected with HIV-1, HIV-2 or dually infected, or in case of prevention trials, HIV
uninfected but at risk of infection.
Trial date Reported between 2004 and 2008, if preliminary data only, authors will be contacted
for additional results. Data on ongoing trials will not be extracted until their
completion.
doi:10.1371/journal.pone.0028759.t001
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in South Africa and five in Zambia. Four trials single-centre trials
were conducted in Zimbabwe, three were conducted in Kenya and
Uganda each and Malawi hosted two trials. Mozambique, Nigeria
and Tanzania hosted one trial each. Figure 2 shows the map of
African countries and the number of trials conducted per country.
Principal investigators
The principal investigator (PI) was clearly reported in 21 of the
68 trials. In 17 of the trials the PI was also the corresponding first
author and in one trial the corresponding last author. The PI was
the first author in one and the last author in two of the remaining
trials but not the corresponding author.
Table 2. Data extraction items in included trials.
Item Details recorded
Reference Trial ID; trial title; publication details
Intervention
Dates
Prevention; treatment
Trial start and end dates; duration of follow-up; early termination
Location Single or multi-centre; city; region; country; details of other countries if multinational.
Principal investigator Name; affiliation; qualifications; country of residence; address where available
Funders Location (African or non-African); government agency; non-governmental agency; pharmaceutical company
Ethical approval Location (African or non-African); method of informed consent
Methods Sample size; power calculation; generation of allocation sequence; allocation concealment; blinding; loss to follow-up
doi:10.1371/journal.pone.0028759.t002
Figure 1. Flow diagram showing the assessment of African trials for 2004–2008 in the HIV register.
doi:10.1371/journal.pone.0028759.g001
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as the PI for further analysis. Most principal investigators, both the
clearly stated and the assumed, were based in the USA (29) and in
the United Kingdom (10), with 18 PIs residing in Africa: in South
Africa (8), Zambia (5) Uganda (2), Kenya (1), Rwanda (1), and in
Nigeria (1). The other non-African PIs resided in Denmark (3),
France (1), Netherlands (1), Canada (1) and India (1). The
locations of four PIs could not be identified.
Qualifications of the PIs were generally not reported. Of the 18
reported, seven had PhD degrees, six medical degrees, three had
both medical and PhD degrees and two had medical and Masters
degrees.
Trial types
Forty-three RCTs assessed interventions for the prevention of
HIV and related infections, while 25 assessed interventions for the
treatment of AIDS and related infections.
Prevention trials. Of the 43 prevention trials, 15 (35%)
investigated the prevention of mother-to-child transmission of
HIV. Behavioural interventions and microbicides were
investigated in five trials each. Six trials investigated the use of
pharmaceutical products for the prevention of opportunistic
infections in HIV-infected participants, while one trial evaluated
pharmaceutical products for HIV. Other trials investigated the
effects of male circumcision (3) and nutritional interventions in
HIV-infected participants (4). Four other trials investigated
interventions to improve the uptake of HIV counselling and
testing, the use of contraception methods, planning for the future
by HIV-infected couples and the prevention of malaria in HIV-
infected patients. We did not identify any trials for vaccine
efficacy.
Treatment trials. Twelve (48%) of the 25 treatment trials
focused on pharmaceutical products for the treatment of
opportunistic infections and three investigated pharmaceutical
products for the treatment of AIDS. Others investigated the use of
pharmaceutical products for other infections in HIV-infected
people (3), the effects of nutritional interventions (4), the effects of
exercise (1), delivery of highly-active antiretroviral therapy
(HAART) by direct observation (1) and interventions for treating
bacterial vaginosis (1).
Trial Dates
Twenty-one trials reported both the month and year participant
enrolment into the trial began and ended, and the month and year
the trial was completed. Nineteen reported the month and year
when participant enrolment began and ended, but did not report
the trial completion dates. Twelve reported the month and year
the trial started and ended, but did not report the dates of
participant enrolment. Ten RCTs reported some dates, e.g. trial
start and end years with no months or the month and year the trial
started without reporting the end dates. In six of the trials no dates
were reported.
The first trial commenced in 1994 and investigated the
treatment of AIDS-associated Kaposi’s sarcoma in Zimbabwe
[9]. Nine trials commenced before the year 2000. The last five
trials began in 2005 and two of these ended in 2007.
Figure 2. The countries where the trials were conducted.
doi:10.1371/journal.pone.0028759.g002
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The median sample size was 626 participants. The sample size
ranged from 33 participants in a trial investigating the treatment of
Kaposi’s sarcoma conducted in Durban, South Africa [10] to 9645
participants in a behavioural intervention trial conducted in the
Mwanza region in Tanzania [11]. In 31 RCTs, the number of
participants was less than or equal to 500, with four RCTs
including more than 5000 participants (see Figure 3).
In 54 trials, the sample size and power calculation based on the
primary outcome was conducted before the trial began. In
fourteen trials there was no report of power calculation. The
primary outcome was clearly indicated in 56 trials, while 12 trials
did not report which of the outcomes was the primary outcome.
Number of intervention groups and types of
randomization
Fifty-seven trials compared two interventions, six compared
three and five compared four interventions with each other. In 43
trials participants were randomized at the individual level, while
17 trials randomized mother and child pairs. One trial
randomized couples. There were six cluster trials and one cross-
over trial. Three cluster trials investigated behavioural interven-
tions, two investigated the prevention of other infections in HIV-
infected participants and one investigated the use of pharmaceu-
tical products for the prevention of opportunistic infections in
HIV- infected participants.
The quality of methods
Generation of the randomization sequence. We judged
the methods used to generate the random sequence to be free of
bias in 38 trials. The methods used to generate the randomization
sequence included a computer-generated list (31), a randomized
list generated by a statistician (2), a random number list/table (2),
and a randomized list prepared off-site (1). In one trial, the
methods were only described as permuted without any further
description [12] and coin tossing was used in one trial [13]. In 30
trials we could not determine the methods used to generate the
random sequence.
Allocation concealment. Methods used for allocation
concealment was assessed to be free of bias in 35 trials. These
included the use of sequentially numbered, sealed, opaque or
padded envelopes in 14 trials, treatment given in identical, non-
transparent and sequentially numbered containers (11), the
randomization list kept in sealed envelopes drawn independently
and sequentially (5), the code or the list held off-site with no access
by the investigators (4) and centralized randomization (1). Methods
for allocation concealment were not adequately described in 32
trials. The allocation sequence was inadequately concealed in one
trial, where the first 17 participants were assigned to one
intervention and randomization started on the 18
th participant.
Blinding of providers, participants and outcome
assessors. Eighteen trials clearly stated that providers,
participants and outcome assessors were blinded to the
interventions into which the participants were allocated. In six
trials, providers and participants were blinded, but it was unclear
whether the outcome assessors were blinded. Twenty-four trials
blinded the providers, 33 blinded the participants and 31 blinded
the outcome assessors. Providers were not blinded in 30 trials and
participants were not blinded in 29 trials, however, outcome
assessors were blinded in 12 of these trials. Table 3 shows the
blinding of providers, participants and outcome assessors.
Consort flow diagram
A CONSORT flow diagram was included in 58 trials, clearly
showing loss to follow-up. In 10 trials, the CONSORT flow
diagram was not included.
Early termination
Thirteen trials were terminated earlier than planned. Reasons
for early termination included a significant effect of the
intervention detected during data monitoring [14–18] and no
significant effect during data monitoring [19–21]. In two of these
trials, the results of data monitoring were confirmed in a recently
published trial employing the same intervention [20,21]. A
possible increase in the risk in the intervention arm was cited in
two trials [22,23], in both, the decision to review the data was
taken due to the publication of a related trial. In one trial [24], the
US Food and Drug Administration recommended against the
prolonged use of Nevirapine by women with CD4 counts $250
cells/mm
3, thus the intervention was terminated. Non-compliance
Figure 3. The ranges of the sample size in the trials.
doi:10.1371/journal.pone.0028759.g003
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interest [26] were cited as reasons in one trial each.
Ethics approval and informed consent
Sixty-six trials reported receiving ethical approval and two trials
did not report on ethical approval. Fifty-seven received approval
from both African and non-African ethics review committees,
eight reported receiving ethical review from African countries
without mentioning international ethics review-boards, while one
trial reported receiving ethical approval but did not state the name
and location of the approving body. Of the eight trials that
reported ethical approval only from African bodies, seven reported
non-African funding agencies. Written informed consent was
obtained from participants in 52 trials, and one trial obtained
consent orally. Eight trials reported receiving consent, but the type
of consent was not specified. Informed consent was not reported in
seven trials.
Funding
Fifty-eight trials were funded by multiple organisations and the
primary funder could not be identified. Nine trials had a single
funder. One trial [27] did not report on funding.
Government Agencies. Eight RCTs were funded by African
government agencies; five agencies were from South Africa
(National Institute for Communicable Diseases; National
Research Foundation; Medical Research Council of South
Africa; University of Cape Town and Rhodes University), two
from Zimbabwe (Ministry of Health and Child Welfare, and
University of Zimbabwe) and one from Rwanda (Multi-sectoral
AIDS Program). None of the trials was solely funded by African
government agencies. The majority of funding was obtained from
non-African governments. Table 4 shows the details of non-
African government agencies funding the trials.
Non-governmental agencies. Five African non-
governmental agencies funded four trials; from South Africa
(Africa Centre for Health and Population Studies), Malawi
(Blantyre Christian Centre, and Wellcome Trust Laboratories in
Malawi) and Zimbabwe (Jewish Humanitarian & Relief
Committee and The Salvation Army). Non-African non-
governmental agencies included Fogarty International (8),
Wellcome Trust (8), and the Bill and Melinda Gates Foundation
(4). One trial [17] was exclusively funded by a non-governmental
agency (Rockefeller Foundation). USA based non-governmental
agencies provided funding to 33 trials, United Kingdom based
agencies funded eight, while Denmark and Canada based agencies
funded five and one, respectively. The locations of 18 non-
governmental agencies were unclear.
Pharmaceutical and other commercial companies. None
of the trials were exclusively funded by pharmaceutical companies.
Fourteen pharmaceutical companies provided funding to 16 trials.
Funding from pharmaceutical companies included the provision of
drugs, placebo or both. Nine of the trials that received funding from
pharmaceutical companies were co-funded by the US government.
One trial [28] was exclusively funded by a commercial company,
Nestle SA.
Discussion
This study provides a descriptive analysis of African HIV/AIDS
RCTs published from January 2004 to December 2008, and
updates our previous work where we reviewed RCTs published up
to December 2003. The trial reports were obtained from the
Cochrane HIV/AIDS Specialised Register and RCTs conducted
partially or wholly in Africa were included.
Number of trials, investigators and funders
This study identified more trials from South Africa and Zambia
followed by Zimbabwe, Tanzania and Uganda. This is similar to
the findings of a previous study of all RCTs conducted in sub-
Saharan Africa and published up to 1999, which identified that
almost half of the trials were conducted in South Africa [29]. This
most likely reflects the dominant economic role South Africa plays
on the continent and is not only a reflection of prevalence.
Although Swaziland and Lesotho have higher prevalence of HIV
compared to other African countries (26.1 and .23%, respec-
tively), no trials were identified from these countries [1]. The low
number of trials in some African countries with high HIV
prevalence raises concerns about the interests of African
governments and the evidence that drives local policy. Other
factors that may hinder investigators from conducting trials in
resource-constrained countries are difficulties in obtaining cultur-
ally relevant and well understood informed consent, ethical
approval by governing bodies and the availability of infrastructure
[30–32].
African countries often host trials that are led by non-African
researchers [33]. In our study, only 18 (28%) of the principal
investigators (PIs) were based in the continent. Most PIs were
based in the USA and these findings were similar to previous
observations [4,34]. This is likely to indicate a need for capacity
development of local investigators in trials research with the
ultimate aim to ensure the research agenda of the African
continent is driven from within. Non-African based researchers
often conduct research in Africa on behalf of external agencies in
collaboration with African researchers. White argues that these
collaborations can encourage the transfer of skills to African
researchers and ensure that the interests of the host country are
considered when a trial is conducted [33]. The transfer of skills
could further be enforced by the collaboration of experienced
investigators with new researchers. Of the eighteen principal
investigators with reported qualifications, nine had PhD degrees.
The management of research projects and research grants requires
substantial skills and experiences [35], however, we were unable to
assess whether the qualifications of PIs have any impact on the
conduct of trials as the qualifications of PIs were mostly not
reported.
Table 3. Blinding of providers, participants and outcome
assessors.
Provider Participant Assessors Trials
Yes Yes Yes 18
Yes Yes Unclear 6
Unclear Yes Yes 1
Unclear Yes Unclear 8
Unclear Unclear Unclear 4
Unclear No Yes 1
No Unclear Yes 1
No Unclear Unclear 1
No No Yes 10
No No Unclear 14
No No No 4
doi:10.1371/journal.pone.0028759.t003
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one organization, with most funding obtained from USA
governmental agencies followed by United Kingdom governmen-
tal agencies. Few trials were funded by African organizations, in
particular African governments. This is similar to our previous
study which also observed few funders from the continent [4].
Although White argues that international collaborations may be a
vehicle for infrastructural development [33], when research is
funded externally, researchers may become dependent on external
sources, thereby potentially deflecting the priorities from the local
needs [36,37].
Overall, the lack of funding from African governments may
reflect lack of economic ability, political will or capacity to conduct
intervention research [4]. The governments of low- and middle-
income countries, at the Mexico Health Summit in 2005 and at
the World Health Assembly in 2006, committed to spending 2% of
their health budget on health research. These funds are not yet
forthcoming and they need to be delivered and increased to meet
the research needs of the continent [38]. In order to respond to the
health priorities of the continent, African governments need to
prioritize research for informing health policy decisions.
Interventions investigated
As found in our previous study [4], there were more HIV
prevention trials than treatment trials. The prevention trials were
mostly dominated by interventions for the prevention of mother-
to-child transmission of HIV. Few prevention trials were aimed at
preventing HIV infection in sexually active adults. Many were
aimed at preventing opportunistic and other infections in HIV-
infected people. In treatment trials, treatment for opportunistic
and other infections has led treatment research in Africa compared
to pharmaceutical interventions intended for treatment of the
disease itself. Antiretroviral treatment (ART) has only become
available recently in many African countries and remains absent in
others. The difficulty in obtaining and delivering antiretrovirals in
many African settings possibly explains how few trials evaluate
ART.
Methodological quality of trials
In our study, adequate generation of the allocation sequence,
allocation concealment and blinding were not well reported. This
mirrors our previous results, indicating that these aspects of
methodological quality has not improved during our recent study
period [4]. As inadequate allocation concealment and inadequate
blinding are associated with larger treatment effects [39], it is
important that trials be conducted in such a way that the risk of
bias is reduced and that associated methods are adequately
reported. In a study of general paediatric trials published between
1948–2006, there was an increase in the methodological quality of
trials over time, although most still did not report on blinding and
allocation concealment even in a recent period of 2002–2006
[40].In comparing African and North American trials, Siegfried
et al. [34] reported that African trials were more likely to report
adequate generation of the allocation sequence and the allocation
concealment than North American trials. This is contrary to
earlier beliefs that trials of high methodological quality are not
possible in settings of developing countries [41,42]. The authors
speculate that this may be due to the international collaborations
driving African trials, ensuring they fulfill internationals standards
[34].
Other aspects of trial quality were better reported in our study.
The inclusion of a CONSORT-recommended flow diagram has
been found to be associated with improved quality of trial
reporting [43]. In our study 85% of reports included a flow
diagram with clear loss to follow-up of participants. Another
measure of trial quality is the calculation of the sample size and
power of the study. Calculating the sample size prior to conducting
a trial enables the researchers to enroll enough participants to
answer the questions of concern, without subjecting more than the
required participants to interventions that may not work, or be
harmful [44]. Almost 80% of the reports of African trials in our
analysis conform to this convention, showing a greater improve-
ment compared to the earlier observations of 60% [34]. In 82% of
Table 4. Non-African Government agencies providing
funding to trials.
Country Government agency Trials
Canada Canadian Institute for Health Research 1
Canadian International Development Agency 1
St. Michael’s Hospital 1
Denmark Council for Developmental Research 1
Danish International Development Agency 2
Danish Council for Medical Research 1
Danish Embassy in Zimbabwe 1
France Institute Nationale de la Sante et de la Rocherche Medicale1
Ireland Development Cooperation Ireland 1
Switzerland Swiss National Science Foundation 1
World Health Organization 1
Unclear Angece Nationale de Recherches sur le SIDA 1
Commission Nationale le Lutle Centre le SIDA 1
Hearst Fellowship 1
United
Kingdom
Department for International Development 5
European Commission 1
UK Medical Research Council 5
USA Case Western Reserve University 1
Centre for Disease Control and Prevention 4
University of Connecticut 1
Department of Agriculture 1
Department of Health and Human Services 1
National Institute of Health
National Institute for Drug Research 1
National Institute of Allergy and
Infectious Diseases
8
National Institute of Child Health and Human
Development
8
National Institute of Drug Abuse 2
National Institute of Health
(department not specified)
22
National Institute of Mental Health 4
Office of AIDS research (for various
NIH branches and for Universities)
2
US President’s Emergency Plan For AIDS Relief 2
New York State’s Tuition Assistance Programme 1
UN Children’s fund 1
Joint United Nations Programme of HIV/AIDS 2
United States Agency for International Development 11
doi:10.1371/journal.pone.0028759.t004
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such. Previous research has shown that in many research reports,
the primary outcome is omitted, or a new outcome is introduced at
the end of the study, when influenced by statistical significance
already detected [45,46]. Although we did not attempt to review
protocols of the included RCTs to verify if the primary outcome
reported was the intended one at the beginning of the study or not,
we are nevertheless encouraged that this is increasingly well
reported. As prospective clinical trial registration becomes
mandatory [47], comparative analysis of protocols with final
reports will strengthen studies such as ours.
Strengths, limitations and further research
This study reviewed trials published in HIV/AIDS trials
research between 2004 and 2008. The strengths of our study
include the use of our fully functional Specialized Register of
HIV/AIDS clinical trials which is updated quarterly from
searching three major electronic databases. Our search was not
limited by publication language. We used standardized methods
for inclusion criteria and data extraction, and the processes were
independently duplicated by two experienced reviewers. We also
conducted quality control on a random sample of our trials.
This study is based on RCTs published in peer-reviewed
journals and we did not search for unpublished trials from
prospective clinical trials registries and conference proceedings. It
is therefore possible that some trials could have been missed due to
publication bias. Our register will in the near future be advancing
towards including unpublished trials from conference proceedings.
The short duration of our study period did not allow us to
compare trends in the HIV/AIDS- related trials for each year.
Our study reviewed African RCTs, and we did not attempt to
compare them with trials from other locations. This new data
highlights current achievements in research and informs African
stakeholders of gaps we identified. Further studies can build on this
research to observe changes in methodological quality, advances in
interventions over time and comparisons of these parameters with
other settings.
Conclusion
This study shows that the scope of HIV/AIDS research in
Africa has not changed from our previous study including trials up
to 2003. It also shows that the reporting of trial conduct has
improved in some aspects. It highlights the need for African
governmental and non-governmental agencies to be actively
involved in funding research and for African researchers to be
actively involved in leading trials.
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